Company / SG&A Expense
SOLENO THERAPEUTICS INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$132.1M
FY2025
5-year range
$9.8M / $132.1M
FY2021-FY2025
Trend
+24.8%
vs FY2024
Sector context
#98 of 211
Health Care
What the data says
At $132M, SOLENO THERAPEUTICS INC's sg&a expense ranks #114 of 211 in the Health Care sector. SG&A Expense has increased for 3 consecutive years, from $10M in FY2022 to $132M in FY2025.
Based on SEC 10-K filings.
$132M in FY2025 with a 5-year CAGR of +72.1%.
Increased from $13M to $132M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +137.7%
- 5-Year CAGR
- +72.1%
- 10-Year CAGR
- -
Sector benchmark
#114 of 211 in Health CareTop 54% of 211This company $132.1M Sector average $728.7M
▼
-81.9% below sector average
Key checks
Key Insights
- SOLENO THERAPEUTICS INC's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +72.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 24.8% year-over-year.
- Ranks #98 out of 211 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $132.1M | +24.8% |
| FY2024 | $105.9M | +685.3% |
| FY2023 | $13.5M | +36.9% |
| FY2022 | $9.8M | -8.9% |
| FY2021 | $10.8M | +23.4% |
| FY2020 | $8.8M | +26.4% |
| FY2019 | $6.9M | +5.7% |
| FY2018 | $6.6M | -0.4% |
| FY2017 | $6.6M | +8.3% |
| FY2016 | $6.1M | -1.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026